Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia

被引：1

作者：

Sacco, A.

Ghobrial, I. M.

Roccaro, A. M. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

来源：

CURRENT CANCER DRUG TARGETS | 2011年 / 11卷 / 09期

关键词：

Anti-angiogenic approach; Waldenstrom's Macroglobulinemia; IGM MONOCLONAL GAMMOPATHY; SINGLE-AGENT BORTEZOMIB; PHASE-II TRIAL; BONE-MARROW; KAPPA-B; PROTEASOME; INHIBITION; SURVIVAL; TARGET; CELLS;

D O I：

10.2174/156800911798073032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bone marrow microenvironment has been shown to play a crucial role in supporting the pathogenesis and the progression of several B-cell malignancies, including Waldenstrom's Macroglobulinemia (WM). Among the different cell types within the bone marrow milieu, endothelial cells have been proven to support WM cells growth. Based on the understanding of bone marrow neo-angiogenesis in plasma cell dyscrasias, a number of anti-angiogenic molecules are now available for the treatment of these diseases. Indeed, anti-angiogenic drugs, such as proteasome-, proteins kinase-C (PKC)-, phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR)-, and histone deacetylase (HDAC)-inhibitors are now available, playing a key role in the treatment of WM both in the preclinical settings and as part of clinical trials.

引用

收藏

页码：1025 / 1029

页数：5

相关论文

共 50 条

[31] Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide [J].

Dimopoulos, MA ;

Hamilos, G ;

Efstathiou, E ;

Siapkaras, I ;

Matsouka, C ;

Gika, D ;

Grigoraki, V ;

Papadimitriou, C ;

Mitsibounas, D ;

Anagnostopoulos, N .

LEUKEMIA & LYMPHOMA, 2003, 44 (06) :993-996

[32] Ibrutinib for the treatment of Waldenstrom macroglobulinemia [J].

Chakraborty, Rajshekhar ;

Kapoor, Prashant ;

Ansell, Stephen M. ;

Gertz, Morie A. .

EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (05) :569-579

[33] New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia [J].

Issa, Ghayas C. ;

Leblebjian, Houry ;

Roccaro, Aldo M. ;

Ghobrial, Irene M. .

CURRENT OPINION IN HEMATOLOGY, 2011, 18 (04) :260-265

[34] Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling [J].

Simon, Thomas ;

Gagliano, Teresa ;

Giamast, Georgios .

TRENDS IN MOLECULAR MEDICINE, 2017, 23 (03) :282-292

[35] Waldenstrom Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies [J].

Boutilier, Ava J. ;

Huang, Lina ;

Elsawa, Sherine F. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)

[36] Fludarabine in Waldenstrom's macroglobulinemia [J].

Souchet-Compain, Laetitia ;

Stephanie Nguyen ;

Choquet, Sylvain ;

Leblond, Veronique .

EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (03) :229-237

[37] Current options to manage Waldenstrom's macroglobulinemia [J].

Benevolo, Giulia ;

Nicolosi, Maura ;

Santambrogio, Elisa ;

Vitolo, Umberto .

EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (07) :637-647

[38] Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs [J].

Montemagno, Christopher ;

Pages, Gilles .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8

[39] The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia [J].

Gavriatopoulou, Maria ;

Fotiou, Despina ;

Ntanasis-Stathopoulos, Ioannis ;

Dimopoulos, Meletios Athanasios .

EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (08) :663-674

[40] A Canadian Perspective on the Treatment of Waldenstrom Macroglobulinemia [J].

Kaedbey, Rayan ;

Forward, Nicholas ;

Sehn, Laurie H. ;

Shafey, Mona ;

Doucette, Sarah ;

Chen, Christine, I .

CURRENT ONCOLOGY, 2022, 29 (10) :7122-7139

← 1 2 3 4 5 →